Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Silo Pharma, Inc.

Ticker
SILO
Sector
Industry
Report date
November 14, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent developments highlight Silo Pharma's ongoing capital raises, patent allowances, clinical and preclinical study progress, and strategic expansions into AI technology.

Recent developments:
  • Silo Pharma entered into securities purchase agreements for an $815,000 private placement in November 2026 [N1].
  • The company planned to highlight its SPC-15 nose-to-brain technology at the 2026 Nasal Innovation Forum [N2].
  • Silo received a European patent for its preventive PTSD therapy SPC-15 in August 2026 [N3].
  • Silo's QwikAgents platform participated in an AI developer program to advance its AI capabilities in July 2026 [N4].
  • The company expanded into the AI agent market with the QwikAgents platform acquisition in April 2026 [N5].
  • Silo announced plans to advance SPC-15 as a PTSD treatment following a U.S. executive order in April 2026 [N6].
  • Silo and Hoth Therapeutics launched a joint venture to commercialize a VA-invented obesity drug in June 2025 [N7][N8].
Overview

Silo Pharma, Inc. focuses on developing psychedelic-based therapeutic candidates, notably SPC-15 for PTSD and SP-26 for fibromyalgia. The company has secured patent allowances in multiple jurisdictions for SPC-15 and is advancing clinical and preclinical studies. It has formed a joint venture with Hoth Therapeutics to commercialize a VA-developed obesity drug and expanded into AI through the acquisition of the QwikAgents platform. The business operates under stringent regulatory frameworks governing controlled substances, including DEA and FDA regulations, which impact research, manufacturing, and commercialization activities. Financially, the company maintains a strong liquidity position with significant cash reserves and low liabilities as of Q3 2026. The company’s operations are subject to risks related to regulatory approvals, scheduling of controlled substances, and public perception of psychedelic therapies.

Executive summary

Silo Pharma, Inc. is a biotechnology company developing psychedelic-based medicines, including SPC-15 for PTSD treatment, with multiple patent allowances and ongoing clinical studies. The company operates in a highly regulated environment involving controlled substances subject to DEA and FDA oversight. Financially, as of September 30, 2026, it holds approximately $6.1 million in cash and equivalents and reported a net loss of $358,743 for the quarter. Recent capital raises and strategic expansions into AI platforms complement its core pharmaceutical development. Risks include regulatory scheduling uncertainties, compliance burdens, and market acceptance challenges. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. [S2]

Scenarios for SILO

Bull case model:

Silo Pharma has established a robust IP portfolio with patent allowances for SPC-15 across key markets, supporting its development pipeline for PTSD treatment. The company's strategic joint venture for obesity treatment and expansion into AI platforms demonstrate diversification and innovation. Strong liquidity and recent capital raises provide resources to advance clinical programs and regulatory milestones. The evolving regulatory landscape and increasing public awareness of psychedelics-based therapies may facilitate broader acceptance and potential commercialization pathways.

Bear case model:

The company operates in a highly regulated environment with significant risks related to DEA scheduling and FDA approvals, which may delay or restrict commercialization of its product candidates. Regulatory compliance burdens and potential adverse public perception of psychedelic therapies could impact clinical trial progress and market acceptance. The psychedelics industry remains nascent with uncertain market dynamics and competitive pressures. Financial losses and reliance on capital raises highlight ongoing funding risks. Failure to achieve regulatory milestones or market acceptance could materially affect business prospects.

Moat:

Silo Pharma's moat derives from its intellectual property portfolio, including multiple patent allowances for SPC-15, a novel PTSD treatment. Its joint venture with Hoth Therapeutics for a VA-invented obesity drug and expansion into AI agent technology through QwikAgents provide diversified innovation avenues. The company's focus on psychedelic-based medicines in a highly regulated and emerging market creates barriers to entry due to complex regulatory compliance, DEA scheduling requirements, and the need for specialized clinical expertise. These factors collectively contribute to a competitive advantage in the niche psychedelics pharmaceutical sector.

Risks overview
Risks summary
The most significant risks for Silo Pharma stem from regulatory uncertainties related to controlled substance scheduling and compliance, which could materially impact clinical development and commercialization efforts.
Risks details:

• Regulatory and Scheduling Risks: Silo Pharma's product candidates contain controlled substances subject to DEA and FDA regulations, including scheduling under the Controlled Substances Act. Delays or unfavorable scheduling decisions could impede clinical trials, manufacturing, distribution, and commercialization.
• Compliance and Legal Risks: Failure to comply with federal, state, and foreign laws governing controlled substances may result in penalties, enforcement actions, or criminal charges, adversely affecting operations and reputation.
• Market and Industry Risks: The psychedelics industry is emerging and subject to evolving regulations, public perception, and political pressures, which may affect acceptance and commercial success of therapies.
• Clinical Development Risks: Clinical trials are costly and uncertain; failure to demonstrate safety and efficacy could delay or prevent regulatory approvals.
• Financial Risks: The company has reported net losses and depends on capital raises to fund operations, exposing it to liquidity and dilution risks.

FINAL FORECAST FOR SILO

Final take one line
Silo Pharma operates with high visibility in the psychedelics pharmaceutical sector, advancing patented therapies amid regulatory complexities and strategic diversification.
Final take 12 to 24 month view

Business trends: Continued development of psychedelic-based therapies with patent protections and expansion into AI technology.
Execution milestones: Advancement of clinical studies for SPC-15 and SP-26, capital raises, and strategic joint ventures.
Key risks: Regulatory scheduling uncertainties, compliance challenges, clinical trial risks, and evolving market acceptance.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • Silo Pharma, Inc. is a biotechnology company focused on developing psychedelic-based medicines, including therapies containing controlled substances such as psilocybin and ketamine [S1].
  • The company is developing SPC-15, a drug candidate for the treatment and prevention of PTSD, which has received patent allowances in the U.S., Europe, and Canada [N3][N7][N8].
  • Silo Pharma has a joint venture with Hoth Therapeutics to commercialize a VA-invented obesity drug [N7][N8].
  • The company has expanded into the AI agent market through the acquisition of the QwikAgents platform and participates in AI developer programs [N4][N5].
  • Silo Pharma is conducting clinical and preclinical studies, including a drug-device study with Resyca BV for SPC-15 aimed at PTSD treatment and preclinical studies for SP-26, a ketamine implant for fibromyalgia [N5][N6].
  • The company has engaged in multiple private placements and public offerings to raise capital, including an $815,000 private placement in November 2026 and a $1 million share buyback program announced in early 2026 [N1].
  • Financial snapshot as of September 30, 2026, shows cash and equivalents of approximately $6.1 million, short-term investments of $1.96 million, current assets of $8.59 million, and current liabilities of $0.35 million, resulting in a strong current ratio of 24.43 and cash ratio of 22.91 [S2].
  • The company reported a net loss of $358,743 and revenue of $18,026 for the quarter ended September 30, 2026, with basic and diluted EPS of -$0.21 [S2].
  • Silo Pharma operates in a highly regulated environment with its product candidates containing controlled substances subject to DEA and FDA regulations, including scheduling under the Controlled Substances Act, which affects research, manufacturing, distribution, and commercialization [S1].
  • The company faces regulatory risks related to the scheduling status of psilocybin and ketamine, potential delays in clinical trials due to DEA registrations, and compliance with federal, state, and foreign laws [S1].
  • Public perception and political pressures regarding psychedelic therapies may impact the company's regulatory approvals and market acceptance [S1].
  • The psychedelics industry is relatively new and evolving, with uncertainties around market growth, regulatory acceptance, and competitive landscape [S1].
Sources
Sources - Context summary

Generated 2026-11-14

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-27 | 10-K
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-11-07 | www.nasdaq.com | Silo Pharma, Inc. Enters into Securities Purchase Agreements for $815,000 Private Placement | https://www.nasdaq.com/articles/silo-pharma-inc-enters-securities-purchase-agreements-815000-private-placement
  • N2 | 2026-09-09 | www.nasdaq.com | Silo Pharma To Highlight SPC-15 Nose-To-Brain Technology At 2026 Nasal Innovation Forum | https://www.nasdaq.com/articles/silo-pharma-highlight-spc-15-nose-brain-technology-2026-nasal-innovation-forum
  • N3 | 2026-08-10 | www.nasdaq.com | Silo Receives European Patent For Preventive PTSD Therapy SPC-15 | https://www.nasdaq.com/articles/silo-receives-european-patent-preventive-ptsd-therapy-spc-15
  • N4 | 2026-07-15 | www.nasdaq.com | Silo's QwikAgents Participates In AI Developer Program To Advance AI Platform | https://www.nasdaq.com/articles/silos-qwikagents-participates-ai-developer-program-advance-ai-platform
  • N5 | 2026-04-23 | www.nasdaq.com | Silo Pharma Expands Into AI Agent Market With Qwikagents Platform Acquisition; Stock Down | https://www.nasdaq.com/articles/silo-pharma-expands-ai-agent-market-qwikagents-platform-acquisition-stock-down
  • N6 | 2026-04-20 | www.nasdaq.com | Silo Pharma To Advance SPC-15 As PTSD Treatment After U.S. Executive Order | https://www.nasdaq.com/articles/silo-pharma-advance-spc-15-ptsd-treatment-after-us-executive-order
  • N7 | 2025-06-25 | www.nasdaq.com | Hoth Therapeutics, Silo Pharma Launch JV To Commercialize VA-Invented Obesity Drug | https://www.nasdaq.com/articles/hoth-therapeutics-silo-pharma-launch-jv-commercialize-va-invented-obesity-drug
  • N8 | 2025-06-25 | www.nasdaq.com | Silo Pharma and Hoth Therapeutics to Form Joint Venture for VA-Developed Obesity Treatment | https://www.nasdaq.com/articles/silo-pharma-and-hoth-therapeutics-form-joint-venture-va-developed-obesity-treatment
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine